During Q1, Edesa advanced production of its anti-CXCL10 monoclonal antibody candidate EB06 and matching placebo ahead of a planned Phase 2 study in moderate-to-severe nonsegmental vitiligo. The company targets mid-2026 for patient recruitment, subject to regulatory clearance, and is on schedule with clinical drug supply manufacturing.

Following positive Phase 3 results in Acute Respiratory Distress Syndrome, Edesa is evaluating subgroup data to identify additional efficacy signals among patients with specific comorbidities. Management plans to present both full and subgroup analyses at multiple scientific and medical conferences later this year.

For the quarter ended December 31, 2025, total operating expenses climbed to $2.3 million, with R&D at $1.1 million and G&A at $1.2 million. Other income fell to $0.1 million, driving a net loss of $2.2 million ($0.28/share) versus $1.6 million ($0.48/share) a year earlier, while cash and cash equivalents stood at $12.1 million.

Edesa is exploring accelerated commercialization pathways and broader strategic opportunities for paridiprubart, while maintaining disciplined resource deployment. The company will attend several industry conferences—including the Global Vitiligo Symposium and American Thoracic Society meeting—to showcase data and engage potential partners.